BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
NEW ORLEANS (WVUE) - If you have trouble affording prescription drugs, some independent pharmacists say that so-called ...
Growth in Eliquis drug also led to an upside in the top line. Consequently, the company raised its annual earnings guidance. Following this, the stock also rallied. BMY is banking on newer drugs ...
Summary Apixaban is an oral ... regimen in clinical trials without the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination pathways, and its ...
The data forecasts the top 10 best-selling drugs in 2025 by annual revenue. Following Keytruda, Bristol-Myers Squibb (BMS) and Pfizer's Eliquis (apixaban), an oral anticoagulant, will be the ...
Hosted on MSN5d
What's Behind the Insider Buying on This High-Yield Stock?The biopharma industry is on an upward trajectory, driven by groundbreaking advances in treatment options and a rising demand ...
Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...
Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback